Results 71 to 80 of about 47,575 (169)

Evolving phase I oncology trials in the precision medicine era: design, outcomes, and geographic access. [PDF]

ESMO Real World Data Digit Oncol
Katsuya Y, Koyama T, Sato J, Okada M, Yamamoto N.   +4 more
europepmc   +1 more source

Associations between self-management strategies and clinical outcomes in depression: a cross-sectional survey. [PDF]

Front Psychiatry
Tada T, Sakurai H, Maruki T, Murao M, Matsumoto Y, Aoki Y, Tachimori H, Imamura Y, Matsumoto Y, Sawada N, Hongo S, Makino S, Tada K, Tsuboi T, Watanabe K.   +14 more
europepmc   +1 more source

Medication Adherence and Antithrombotic Therapy Outcomes: Insights From a Post Hoc Analysis of the AFIRE Trial. [PDF]

JACC Asia
Chiba N, Noda T, Nochioka K, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, Miyauchi K, Hagiwara N, Kimura K, Matsui K, Ogawa H, Yasuda S, AFIRE Investigators.   +14 more
europepmc   +1 more source

Cerebrospinal fluid ctDNA clarifies clonal divergence: leptomeningeal flare of <i>EGFR</i>-mutant disease after switch to selpercatinib for acquired <i>RET</i> fusion. [PDF]

J Liq Biopsy
Kunimasa K, Tamiya M, Inoue T, Mamesaya N, Tanaka T, Komuta K, Futamura S, Honma K, Nishino K.   +8 more
europepmc   +1 more source

Association Between Muscle Quality and GNRI in Patients with Type 2 Diabetes. [PDF]

Nutrients
Yamamoto S, Hashimoto Y, Takahashi F, Murai M, Yoshioka N, Saijo Y, Munekawa C, Nakajima H, Kitagawa N, Osaka T, Sakai R, Okada H, Nakanishi N, Majima S, Ushigome E, Hamaguchi M, Fukui M.   +16 more
europepmc   +1 more source

Mode of action-specific and cause-specific retention of biologic and targeted synthetic disease-modifying antirheumatic drugs in anti-SS-A antibody-positive rheumatoid arthritis: The ANSWER cohort study. [PDF]

PLoS One
Nishisaka K, Okano T, Imai T, Tsubosaka M, Kamenaga T, Nakano N, Hayashi S, Yamamoto W, Onishi A, Murakami K, Tsujimoto K, Katsushima M, Yoshikawa A, Kotani T, Amuro H, Son Y, Itami T, Nozaki Y, Nose Y, Yamashita M, Shirasugi I, Yamada H, Nishimura K, Ueda Y, Sendo S, Hashimoto M, Kuroda R, Saegusa J.   +27 more
europepmc   +1 more source

Safety and Efficacy of Ozanimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Age. [PDF]

Inflamm Bowel Dis
Faye AS, Rubin DT, Siegel CA, Long MD, Khan N, Danese S, Irving PM, Cross RK, Blumenstein I, Armuzzi A, Horst SN, Dignass A, Kobayashi T, Lawlor G, Krakovich A, Petersen A, Liu Z, Wang D, Jain A, Ananthakrishnan AN, Sabino J.   +20 more
europepmc   +1 more source

Comparison of chemoradiotherapy and gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer: an integrated analysis of two randomized phase II trials (JCOG2408A). [PDF]

BMC Cancer
Sano Y, Kajikawa R, Mizusawa J, Ioka T, Ozaka M, Nakamura S, Ito Y, Furuse J, Kobayashi S, Fukuda H, Okusaka T, Ikeda M, Miwa H, Sasahira N, Nagashima F, Ohkawa K, Yamazaki K, Kanai M, Yamashita T, Hara K, Takayama Y, Komatsu Y, Fujimori N, Hama N, Kamata K, Hisano T, Shimizu S, Tobimatsu K, Maeda S, Ueno M.   +29 more
europepmc   +1 more source

Exploratory analysis of HER2-positive/CLDN18.2-positive metastatic gastric and gastroesophageal junction cancer toward future therapeutic development. [PDF]

ESMO Gastrointest Oncol
Okemoto D, Nakayama I, Shitara K.
europepmc   +1 more source

Efficacy and Safety of Human Epidermal Growth Factor Receptor 2 (HER2) Antibody-Drug Conjugates in Solid Tumors Harboring Non-tyrosine Kinase Domain ERBB2 Mutations: A Systematic Review. [PDF]

Cureus
Ohta R, Fujimori T, Tanaka K, Hayashi H.
europepmc   +1 more source